Long-Term Reality of Single-Ventricle Reconstruction: Shunt Choice, Tricuspid Regurgitation, and the Burden of Global Morbidity

MedXY Editorial Team•Mar 11, 2026•Cardiology

Global morbidity remains exceptionally high, with 87% of SVR trial participants experiencing death or a major complication over 16 years of follow-up.
While overall outcomes did not differ significantly between the Right Ventricle-to-Pulmonary Artery Shunt (RVPAS) and the modified Blalock-Taussig-Thomas Shunt (mBTTS), a critical interaction with baseline tricuspid regurgitation was identified.
Participants with moderate-to-severe pre-Norwood tricuspid regurgitation had significantly worse outcomes and higher mortality when receiving an RVPAS compared to an mBTTS.
Prematurity and clinical site variation remain potent independent predictors of long-term outcomes in single-ventricle disease.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Global morbidity remains exceptionally high, with 87% of SVR trial participants experiencing death or a major complication over 16 years of follow-up.
While overall outcomes did not differ significantly between the Right Ventricle-to-Pulmonary Artery Shunt (RVPAS) and the modified Blalock-Taussig-Thomas Shunt (mBTTS), a critical interaction with baseline tricuspid regurgitation was identified.
Participants with moderate-to-severe pre-Norwood tricuspid regurgitation had significantly worse outcomes and higher mortality when receiving an RVPAS compared to an mBTTS.
Prematurity and clinical site variation remain potent independent predictors of long-term outcomes in single-ventricle disease.